ClinicalTrials.gg
CompletedNCT03483909GestTMSUpdated Apr 29, 2019

Transcranial Magnetic Stimulation to Improve Gesture Control

A Phase 1/2 interventional study of left IFG iTBS and right IPL cTBS in Schizophrenia and Related Disorders, sponsored by University of Bern. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-29.

Sponsored by University of Bern · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The majority of schizophrenia patients is impaired in hand gesture performance, which contributes to poor functional outcome and poor communication skills. The left inferior frontal gyrus (IFG) and the left inferior parietal lobe (IPL) are key nodes of the gesture network, which is less active in patients with schizophrenia. Here, the investigators test single sessions of rTMS/TBS known to either enhance or inhibit local brain activity for app. 1 hour. The investigators aim to determine, which protocol may improve gesture performance in patients and healthy controls. This is a randomized, double-blind, cross-over, placebo-controlled single-center trial in 20 patients with schizophrenia spectrum disorders and 20 healthy controls. Gesture performance will be tested immediately after each TMS session, which are separated by 48 hours. Results of this study will inform larger interventional trials comparing 2 TMS protocols with repeated administration.

Read the detailed description

Schizophrenia is associated with poor social functioning, which is perturbed by deficits in social interaction including nonverbal communication. The use of hand gestures is critical for nonverbal communication, but the majority of schizophrenia patients has severe gesture impairments. Today no intervention may ameliorate gesture impairments. Patients with gesture impairments have altered structure and function of the gesture network, particularly the left inferior frontal gyrus (IFG) and also the left inferior parietal lobe (IPL). Noninvasive brain stimulation techniques may alter local brain function. Repetitive transcranial magnetic stimulation (rTMS) and particularly theta burst stimulation (TBS) for a few mins is a very safe method to alter brain states locally for approximately 1 hour. Indeed, facilitatory stimulation of the left frontal cortex by transcranial direct current stimulation (tDCS) demonstrated improved gesture perception and interpretation in healthy subjects. In addition, inhibitory stimulation with continuous theta burst stimulation (cTBS) over left IFG may perturb gesture performance in healthy subjects. Thus, the investigators hypothesize that local changes of brain activity within the gesture network would change gesture performance. Particularly, facilitatory intermittent theta burst stimulation (iTBS) of the left IFG would improve gesture performance. The investigators will test single sessions of rTMS in healthy subjects and schizophrenia patients. If one of the protocols proves to have superior effects, this result will help to plan interventional trials targeting social interaction deficits in schizophrenia. The aim of the study is to determine the effect of one session of iTBS over the left IFG on gesture performance compared to cTBS over the right IPL (active comparator) and one placebo rTMS sessions. This is a randomized, double-blind, cross-over, placebo-controlled single-center trial in 20 patients with schizophrenia spectrum disorders and 20 healthy controls. After baseline assessment of gesture performance, participants will receive one rTMS protocol at each time point, immediately followed by assessments of gesture performance and dexterity. rTMS sessions will be separated by 48 hours. Gesture performance will be measured with video recorded Test of Upper Limb Apraxia, which is rated blindly according to a manual.

02

Conditions studied

  • Schizophrenia and Related Disorders

Keywords

  • gesture
  • rTMS
  • nonverbal communication
  • schizophrenia
  • psychosis
03

In context

Schizophrenia

3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.

This study's enrollment of 40 is below the median of 71 across 2,944 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

University of Bern is the lead sponsor of 209 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Right handed according to the Edinburgh Handedness Inventory
  • Ability and willingness to participate in the study
  • Ability to provide written
  • Informed Consent as documented by signature (Appendix Informed Consent Form)
  • Spent majority of childhood/adolescence in Switzerland
  • Patients: schizophrenia spectrum disorder according to Diagnostic and Statistical Manual version 5 ()

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breast feeding
  • Metal objects on or in the body (e.g. grenade splinter, cardiac pacemaker, vessel clips, metal prostheses, coil, cochlear implants, hearing aid, tooth implant)
  • History of neurosurgery, any severe head wounds, history of neurologic disorders impacting gesture, e.g. Parkinson's disease, stroke, multiple sclerosis sclerosis and epilepsy, convulsion or seizure
  • History of any hearing problems or ringing in the ears.
  • Active drug addiction except nicotine
  • Controls: first-degree relatives with schizophrenia spectrum disorders
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    left IFG iTBS

    intermittent theta burst stimulation over the left inferior frontal gyrus

    Device: left IFG iTBS

  • Active comparator
    right IPL cTBS

    continuous theta burst stimulation over the right inferior parietal cortex

    Device: right IPL cTBS

  • Placebo comparator
    placebo

    Placebo TMS stimulation over the left inferior parietal cortex

    Device: Placebo

Interventions

  • Deviceleft IFG iTBS

    15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4

  • Deviceright IPL cTBS

    15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4

  • DevicePlacebo

    rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL

06

What researchers measure

Primary outcomes

  1. Test of Upper Limb Apraxia

    Standardized gesture performance test, video recorded and rated according to manual by a rater blind to treatment and group

    Time frame: 10 mins after baseline assessment

  2. Test of Upper Limb Apraxia

    Standardized gesture performance test, video recorded and rated according to manual by a rater blind to treatment

    Time frame: 10 mins after left IFG iTBS

  3. Test of Upper Limb Apraxia

    Standardized gesture performance test, video recorded and rated according to manual by a rater blind to treatment

    Time frame: 10 mins after right IPL cTBS

  4. Test of Upper Limb Apraxia

    Standardized gesture performance test, video recorded and rated according to manual by a rater blind to treatment

    Time frame: 10 min after placebo stimulation

Secondary outcomes

  1. Coin rotation

    Test of dexterity, 3 trials of 10s to rotate a .5 Swiss Francs (SFr) coin between thumb, index and middle finger, video recorded, rated blindly according to number of coin half turns

    Time frame: 20 min after baseline assessment

  2. Coin rotation

    Test of dexterity, 3 trials of 10s to rotate a .5 SFr coin between thumb, index and middle finger, video recorded, rated blindly according to number of coin half turns

    Time frame: 20 min after left IFG iTBS

  3. Coin rotation

    Test of dexterity, 3 trials of 10s to rotate a .5 SFr coin between thumb, index and middle finger, video recorded, rated blindly according to number of coin half turns

    Time frame: 20 min after right IPL cTBS

  4. Coin rotation

    Test of dexterity, 3 trials of 10s to rotate a .5 SFr coin between thumb, index and middle finger, video recorded, rated blindly according to number of coin half turns

    Time frame: 20 min after placebo stimulation

07

Study locations

1 site
  • University Hospital of Psychiatry
    Bern, 3000, Switzerland
08

References and documents

Individual participant data

Plan to share: No — The investigators do not plan to share the data, because they cannot anonymize the video data sufficiently

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Apr 2019, 14 months.

Of 18 phase 1/2 interventional studies under Schizophrenia, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 70. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2018
First posted
Mar 30, 2018
StartActual
Jan 29, 2018
Primary completionActual
Apr 1, 2019
CompletionActual
Apr 23, 2019
Last update
Apr 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03483909
Lead sponsor
University of Bern
Responsible party
Sponsor
First posted
Mar 30, 2018
Start date
Jan 29, 2018
Primary completion
Apr 1, 2019
Completion
Apr 23, 2019
Last update
Apr 29, 2019

Study contacts

Sebastian Walther, MD
principal investigator · University of Bern, University Hospital of Psychiatry

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion